AVEO PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 115
- Market Cap
- -
- Website
- http://www.aveooncology.com
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01745367
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT01673386
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
Phase 1
Completed
- Conditions
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01631097
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01603979
- Locations
- 🇺🇸
AVEO Clinical Site, San Antonio, Texas, United States
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT01478594
- Locations
- 🇺🇸
Kaiser Foundation Hospitals, Honolulu, Hawaii, United States
🇨🇦Hopital Saint-Luc - Pavillon Principal, Montreal, Quebec, Canada
🇺🇸Associates of Oncology Hematology, P.C., Rockville, Maryland, United States
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT01369433
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇦AVEO Investigational Site, Zaporizhya, Ukraine
🇺🇸Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC, Metairie, Louisiana, United States
A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01363804
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Daytona Beach, Florida, United States
A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01363778
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01316848
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01306630
© Copyright 2024. All Rights Reserved by MedPath